EAST NORRITON, Pa., May 26 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that its scientists have presented new research data in three podium presentations at the 16th Annual Meeting of the International Society for Cellular Therapy (ISCT) which was held May 23-26 in Philadelphia. These presentations highlighted key findings in Tengion's Neo-Urinary Conduit and Neo-Kidney Augment programs and provided further information about the company's work with various cell types -- adipose-derived smooth muscle cells and human kidney cells -- that support its current and planned clinical development programs.
"Our scientists and discovery team continues to build a robust base of scientific data and technology support that we feel strongly positions these programs for success. We look forward to additional preclinical and clinical data presentations this year," stated Tim Bertram, D.V.M., Ph.D., Senior Vice President of Science and Technology for Tengion. Scientific data presented at ISCT successfully demonstrate that an adipose tissue -- or fatty tissue -- biopsy could be a source of healthy smooth muscle cells which are then used in Tengion's manufacturing process to manufacture an autologous neo-organ. This method eliminates the need to procure cells from a failing or cancerous organ. These research findings support Tengion's lead product candidate, the Neo-Urinary Conduit, which is currently utilizing the adipose tissue biopsy method in an open-label, single-arm Phase I clinical trial in patients with bladder cancer. The Neo-Urinary Conduit is an autologous -- made from a patient's own cells
|SOURCE Tengion Inc.|
Copyright©2010 PR Newswire.
All rights reserved